Drug Trial Radar · NCT03396874
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Last checked: Nov 19, 2026Latest source record: Nov 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,435
Actual
Start
Feb 9, 2018
Primary completion
Aug 9, 2022
Study completion Aug 9, 2022
Sponsor
- Lead sponsor
- University of MichiganAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the value of Gallium-68 labeled PSMA (68Ga-PSMA) for PET/CT imaging of prostate cancer recurrence. 68Ga-PSMA is a radioactive molecule, which binds to prostate cancer cells. Together with a PET/CT scanner, the distribution of 68Ga-PSMA can be determined in the body. To test this new drug, participants will receive an intravenous injection of Ga-68-PSMA and then have a PET/CT scan. The scan results will be made available to study participants and treating physicians.
Conditions
- Prostate Cancer
- Prostate Adenocarcinoma
- Prostate Cancer Metastatic
- Prostate Cancer Recurrent
Interventions
68Ga-PSMADrug
PET/CT imaging with 68Ga-PSMA: 68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Positive Predictive Value (PPV) of 68Ga PSMA PET/CT for Detecting Prostate Cancer on a Per-patient Basis Confirmed by Histopathology.Time frame: Up to 12 months after 68Ga-PSMA scan
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Michigan
Ann Arbor, Michigan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.